Sponsor Dossier
Amdipharm Mercury
Sponsor Dossier for Amdipharm Mercury. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ANDROCUR
- Brand: ANDROCUR-100
- Brand: APRESOLINE
- Brand: COBAL-B12
- Brand: CYCLONEX
- Brand: DIBENYLINE
- Brand: ERYTHROCIN
- Brand: HYGROTON
About
Amdipharm Mercury is an Australian Private Company with ABN 91118106684, registered in NSW and currently active. The company operates under the trading name Mercury Pharma (Australia).
Portfolio
Amdipharm Mercury has 25 brands on the ARTG, of which 23 are indexable and 22 carry a Product Information document. 15 brands are PBS-listed, 6 have a PBAC outcome on record, and 3 have an AusPAR on record. Notable brands include ANDROCUR, ANDROCUR-100, APRESOLINE, COBAL-B12, CYCLONEX, DIBENYLINE, ERYTHROCIN, HYGROTON, LOCACORTEN-VIOFORM, MYTOLAC, NEO-MERCAZOLE, NortriTABS.
Therapeutic focus
— Psychiatry: 5 brands — Endocrinology: 4 brands — Oncology: 3 brands — Haematology: 2 brands — Gastroenterology: 2 brands — Cardiology: 2 brands — Infectious Disease: 1 brand — Musculoskeletal: 1 brand — Neurology: 1 brand — Dermatology: 1 brand — Reproductive Health: 1 brand — Hepatology: 1 brand — Rare Disease: 1 brand
PBS footprint
15 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2022-11-01, across 6 brands with a PBAC outcome on record. The latest AusPAR is 2013-10-11, across 3 brands with an AusPAR on record.